Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation.
Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation.
复制标题
DOI：
10.1371/journal.pone.0200943
复制
发表时间：
2018
期刊：
影响因子：
3.7
通讯作者：
Koike K
中科院分区：
文献类型：
--
作者：
Uchino K;Tateishi R;Nakagomi R;Fujiwara N;Minami T;Sato M;Enooku K;Nakagawa H;Asaoka Y;Kondo Y;Shibahara J;Shiina S;Koike K
肝脏铁蓄积可加速各种慢性肝病患者的肝损伤，导致肝癌发生。我们在一个大型队列中阐明了血清铁蛋白水平对射频消融 (RFA) 后肝细胞癌 (HCC) 预后的影响。我们回顾性分析了 578 名接受 RFA 治疗的初治 HCC 患者。我们根据血清铁蛋白水平的四分位点将队列分为四组：G1（≤55 ng/mL，n = 148）、G2（56-130 ng/mL，n = 142）、G3（131-243 ng/mL，n = 144）和G4（≥244 ng/mL，n = 144）。我们使用 Kaplan-Meier 方法分析了患者的复发和生存。我们还评估了小于 2 cm 的孤立肿瘤患者的病理铁沉积。 5年总复发率和累计生存率分别为81.6%和66.3%。血清铁蛋白水平与病理性铁沉积相关。根据血清铁蛋白水平和病理性肝铁沉积情况，复发率和生存率没有显着差异。血清铁蛋白水平不影响接受 RFA 的 HCC 患者的预后。
Hepatic iron accumulation can accelerate liver injury in patients with various chronic liver diseases and lead to hepatocarcinogenesis. We elucidated the impact of serum levels of ferritin on the prognosis of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) in a large cohort. We retrospectively analyzed 578 treatment-naïve HCC patients who underwent RFA. We divided our cohort into four groups by the quartile points of serum ferritin level: G1 (≤55 ng/mL, n = 148), G2 (56–130 ng/mL, n = 142), G3 (131–243 ng/mL, n = 144) and G4 (≥244 ng/mL, n = 144). We analyzed the recurrence and survival of patients using the Kaplan–Meier method. We also evaluated pathological iron deposition among patients with a solitary tumor smaller than 2 cm. The cumulative rates of overall recurrence and survival at 5 years were 81.6% and 66.3%, respectively. The serum levels of ferritin were correlated with pathological iron deposition. There were no significant differences in recurrence and survival rates according to serum levels of ferritin and pathological hepatic iron deposition. Serum levels of ferritin do not affect the prognosis of HCC patients undergoing RFA.
登录
查看更多内容
影响因子：
29.4
作者：
Lambrecht RW;Sterling RK;Naishadham D;Stoddard AM;Rogers T;Morishima C;Morgan TR;Bonkovsky HL;HALT-C Trial Group
通讯作者：
HALT-C Trial Group
影响因子：
19.7
作者：
Goldberg, SN;Grassi, CJ;Silverman, SG
通讯作者：
Silverman, SG
影响因子：
13.5
作者：
Bedossa, P;Poynard, T
通讯作者：
Poynard, T
影响因子：
29.4
作者：
Niederau, C;Fischer, R;Strohmeyer, G
通讯作者：
Strohmeyer, G
影响因子：
6.7
作者：
Hagstrom, Hannes;Nasr, Patrik;Stal, Per
通讯作者：
Stal, Per